帕金森氏症市场报告：2030 年趋势、预测和竞争分析

帕金森氏症的趋势和预测

预计到 2030 年，全球帕金森氏症市场将达到 88 亿美元，2024 年至 2030 年年复合成长率为 6.1%。该市场的主要驱动力是高龄化的加剧、诊断技术的进步以及新兴国家医疗保健支出的增加。全球帕金森氏症市场未来性广阔，碳度巴/左旋多巴、多巴胺促效剂、MAO-B抑制剂、COMT抑制剂、抗胆碱能药物市场蕴藏商机。

帕金森氏症市场洞察

Lucintel 预计，由于易于获取，零售药局在预测期内仍将是最大的细分市场。

由于北美地区参与者众多、可支配所得高、医疗成本高以及该地区完善的医疗保健系统，因此在预测期内，北美将继续成为最大的地区。

本报告回答了 11 个关键问题：

• Q.1. 细分市场中最有前途和高成长的机会是什么？
• Q.2. 未来哪个细分市场成长较快？为什么？
• Q.3.您认为哪些地区未来会出现更快的成长？为什么？
• Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
• Q.5. 这个市场的商业风险和竞争威胁是什么？
• Q.6.这个市场有哪些新趋势？为什么？
• Q.7.市场客户需求有何改变？
• Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
• Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
• Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
• Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球帕金森氏症市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球帕金森氏症市场趋势（2018-2023）与预测（2024-2030）
• 按药物类别分類的全球帕金森氏症市场
  • Carbidopa-Levodopa
  • 多巴胺促效剂
  • MAO-B抑制剂
  • COMT抑制剂
  • 抗胆碱能药物
  • 其他的
• 按配销通路分類的全球帕金森氏症市场
  • 医院药房
  • 零售药房
  • 线上药房

第4章2018-2030年分地区市场趋势及预测分析

• 全球帕金森氏症市场区域分布
• 北美帕金森氏症市场
• 欧洲帕金森氏症市场
• 亚太帕金森氏症市场
• 其他区域帕金森氏症市场

第5章竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第6章成长机会与策略分析

• 成长机会分析
  • 按药物类别分類的全球帕金森氏症市场成长机会
  • 全球帕金森氏症市场成长机会（按配销通路）
  • 全球帕金森氏症市场成长机会（按地区）
• 全球帕金森氏症市场的新兴趋势
• 战略分析
  • 新产品开发
  • 扩大全球帕金森氏症市场的产能
  • 全球帕金森氏症市场的合併、收购和合资企业
  • 认证和许可

第7章主要企业概况

• Cerevel Therapeutics
• Novartis
• Teva Pharmaceutical Industries
• Merck & Co.
• GlaxoSmithKline
• AbbVie
• H. Lundbeck

Parkinson Disease Trends and Forecast

The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets. The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030 with a CAGR of 6.1% from 2024 to 2030. The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.

A more than 150-page report is developed to help in your business decisions.

Parkinson Disease by Segment

The study includes a forecast for the global parkinson disease by drug class, distribution channel, and region.

Parkinson Disease Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• Carbidopa-Levodopa
• Dopamine Agonists
• Mao-B Inhibitors
• Comt Inhibitors
• Anticholinergics
• Others

Parkinson Disease Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Parkinson Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Parkinson Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies parkinson disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the parkinson disease companies profiled in this report include-

• Cerevel Therapeutics
• Novartis
• Teva Pharmaceutical Industries
• Merck & Co.
• GlaxoSmithKline
• AbbVie
• H. Lundbeck

Parkinson Disease Market Insights

Lucintel forecasts that retail pharmacy will remain the largest segment over the forecast period due to ease of availbility.

North America will remain the largest region over the forecast period due to large number of important participants, high disposable income, high costs for healthcare, and an established healthcare system in this area.

Features of the Global Parkinson Disease Market

Market Size Estimates: Parkinson disease market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Parkinson disease market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Parkinson disease market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, distribution channel, and regions for the parkinson disease market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the parkinson disease market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the parkinson disease market size?

Answer: The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030.

Q2. What is the growth forecast for parkinson disease market?

Answer: The global parkinson disease market is expected to grow with a CAGR of 6.1% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the parkinson disease market?

Answer: The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.

Q4. What are the major segments for parkinson disease market?

Answer: The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets.

Q5. Who are the key parkinson disease market companies?

Answer: Some of the key parkinson disease companies are as follows:

• Cerevel Therapeutics
• Novartis
• Teva Pharmaceutical Industries
• Merck & Co.
• GlaxoSmithKline
• AbbVie
• H. Lundbeck

Q6. Which parkinson disease market segment will be the largest in future?

Answer: Lucintel forecasts that retail pharmacy will remain the largest segment over the forecast period due to ease of availbility.

Q7. In parkinson disease market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to large number of important participants, high disposable income, high costs for healthcare, and an established healthcare system in this area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the parkinson disease market by drug class (carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, anticholinergics, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Parkinson Disease Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Parkinson Disease Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Parkinson Disease Market by Drug Class
  • 3.3.1: Carbidopa-Levodopa
  • 3.3.2: Dopamine Agonists
  • 3.3.3: MAO-B Inhibitors
  • 3.3.4: COMT Inhibitors
  • 3.3.5: Anticholinergics
  • 3.3.6: Others
• 3.4: Global Parkinson Disease Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Online Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Parkinson Disease Market by Region
• 4.2: North American Parkinson Disease Market
  • 4.2.2: North American Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
• 4.3: European Parkinson Disease Market
  • 4.3.1: European Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
  • 4.3.2: European Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
• 4.4: APAC Parkinson Disease Market
  • 4.4.1: APAC Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
  • 4.4.2: APAC Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
• 4.5: ROW Parkinson Disease Market
  • 4.5.1: ROW Parkinson Disease Market by Drug Class: Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, and Others
  • 4.5.2: ROW Parkinson Disease Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Parkinson Disease Market by Drug Class
  • 6.1.2: Growth Opportunities for the Global Parkinson Disease Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Parkinson Disease Market by Region
• 6.2: Emerging Trends in the Global Parkinson Disease Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Parkinson Disease Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Parkinson Disease Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Cerevel Therapeutics
• 7.2: Novartis
• 7.3: Teva Pharmaceutical Industries
• 7.4: Merck & Co.
• 7.5: GlaxoSmithKline
• 7.6: AbbVie
• 7.7: H. Lundbeck